醫師代碼：25019 
專 長
．內科癌症
．血癌
．骨髓移植
現 職
．花蓮慈濟醫院血液腫瘤科主任
．花蓮慈濟醫院骨髓幹細胞中心骨髓幹細胞中心副主任
．花蓮慈濟醫院骨髓幹細胞中心免疫基因實驗室副主任
．慈濟大學醫學系專任副教授
學 歷
．慈濟大學醫學系
經 歷
．花蓮慈濟醫院內科部總住院醫師
．花蓮慈濟醫院血液腫瘤科住院總醫師
．台北慈濟醫院血液腫瘤科主治醫師
．美國國防部Bill Young骨髓捐贈計畫HLA實驗室訪問學者
．美國Fred Hutchinson癌症研究中心臨床免疫基因實驗室訪問學者
．花蓮慈濟醫院研究部臨床試驗中心主任
專科證書
．內科專科醫師
．腫瘤內科專科醫師
．血液及骨髓移植專科醫師
論文著作
1. Wang TF, Chen SH, Yang SH, Su YC, Chu SC, Li DK*. Poor harvest of peripheral blood stem cell in donors with microcytic red blood cell. Transfusion. 2013;53(1):91-5. (SCI)
2. Chen SH, Wang TF, Yang KL*. Hematopoietic Stem Cell Donation. Int J Hematol. 2013;97(4):446-55. (SCI)
3. Wang TF, Wen SH, Yang KL, Yang SH, Yang YF, Chang CY, Wu YF, Chen SH*. Reasons for exclusion of 6820 umbilical cord blood donations in a public cord blood bank. Transfusion. 2014;54(1):231-237. (SCI)
4. Huang WH, Li MS, Chu SC, Wang TF, Kao RH, Wu YF*. Thalidomide treatment in a myelofibrosis patient with leukemia transformation. Int J Hematol. 2014;99(2):188-192. (SCI)
5. Chu SC, Wang TF*, Su YC, Kao RH, Wu YF, Li DK, Li SC, Li CC, Wells DA, Loken MR. Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission. Int J Hematol. 2014 Mar;99(3):296-304. (SCI) (Corresponding author)
6. Chu SC, Hsieh CJ, Wang TF, Hong MK, Chu TY*. Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study. Cancer Epidemiol. 2017 Mar 17;48:22-28. (SCI)
7. Wang TF, Chu SC, Lee JJ, Yang GG, Huang WH, Chang ET, Low T, Wu YF, Kao RH, Lin CB*. Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor–mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. Asia Pac J Clin Oncol. 2017;13(4):304-313. (SCI)
8. Hsieh HJ, Hsu YH, Wang TF, Kao RH, Kao PF*. Hemophagocytic Syndrome in Gallium-67 Scintigraphy. Annals of Nuclear Medicine and Molecular Imaging 2017;30:176-180.
9. Huang CH, Wang TF, Wu YF, Cheng YT, Lo SF, Hsieh TC, Peng TC. Efficacy of Enteral Access in Patients with Esophageal Squamous Cell Carcinoma Under Neoadjuvant Therapy. Anticancer Res. 2018 Dec;38(12):6939-6945.
10. Yang SH, Wan HL, Gu MH, Yang KL, Wang TF* Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor. Tzu Chi Med J 2019 Jan-Mar;31(1):60-62. (Corresponding author)
11. Wu YF, Chu SC, Chang BS, Cheng YT, Wang TF*. Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy. Biomed Res Int. 2019 Jan 29;2019:1263050.
12. Lee CC, Chang HH, Lu MY, Yang YL, Chou SW, Lin DT, Jou ST, Yao M, Li CC, Yeh SP, Chen MH, Gau JP, Li SS, Wang PN, Liu YC, Wang TF, Tan TD, Lee MY, Yu MS, Wang CC, Lin SC, Chen YC, Su YC, Su KY, Lin KH. The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan. Ann Hematol. 2019 Mar;98(3):745-752.
13. Huang CH, Hsieh TC, Chang BS, Wang TF, Wu JL, Chang PC, Peng TC. Enteral Access Potentially Endangers Esophageal Carcinoma Patients Under Multi-modality Therapy: A Population-based Study. Anticancer Res. 2019 Apr;39(4):2227-2232.
14. Wu YF, Gu MH, Yang SH, Wang TF*. Lower platelet count with increased density of platelet antigens in granulocyte colony-stimulating factor mobilized peripheral blood stem cell donors. J Formos Med Assoc. 2019 Apr 16 doi: 10.1016/j.jfma.2019.04.003. [Epub ahead of print]
